Image Trademark with Serial Number 88508018
Status: 732 - Third Extension - Granted
Image for trademark with serial number 88508018
Serial Number
88508018
Status
732 - Third Extension - Granted
Status Date
2021-11-09
Filing Date
2019-07-10
Mark Drawing
2000 - Illustration: Drawing or design without any word(s)/letter(s)/ number(s) Typeset
Design Searches
260121, 261725 - Circles that are totally or partially shaded. Other lines, bands or bars.
Published for Opposition Date
2020-04-07
Attorney Name
Law Office Assigned Location Code
L80
Employee Name
TURNER, JASON FITZGERA
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of a squiggle design with a dot appearing above the right side of the squiggle.
Goods and Services
Pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; Pharmaceuticals used to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases; pharmaceuticals used to prevent disease in the nature of allergies and disrupted microbial community associated with allergies; Pharmaceuticals used to prevent disease in the nature of metabolic disorders; pharmaceuticals used to prevent cardiovascular, neuro-degenerative, and neuro-psychiatric diseases; pharmaceuticals used to treat and cure cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community as sociated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure allergies and disrupted microbial community associated with allergies in human and animal subjects; pharmaceuticals used to treat and cure metabolic disorders and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of inflammation, neuro-inflammatio n, and autoimmune diseases and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of allergies and disrupted microbial community associated with allergies; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of metabolic disorders and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with the aforementioned conditions; bacterial preparations, namely, live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations for medical or veterinary purposes; biological preparations in the nature of of live bacteria, inactivated bacteria, recombinant bacte ria and bacterial extract preparations to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to prevent disease in the nature of allergies in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to prevent disease in the nature of metabolic disorders in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract p reparations to prevent disease in the nature of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of cultures of microorganisms to treat and cure cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to treat and cure inflammation, neuro-inflammation, and autoimmune diseases in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to treat and cure allergies in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to treat and cure metabolic disorders and cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases in animal or human subjects; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to maintain and restore health in animal or human subjects via treatment of inflammation, neuro-inflammation, autoimmune diseases, allergies, metabolic disorders, cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations to maintain and restore health in animal or human subjects via treatment of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; live bacteria, inactivated bacteria, recombinant bacteria and bacterial extract preparations; cultures of microorganisms in the nature of bacterial and bacteriological preparations, all for medical and veterinary purposes, the foregoing for medical purpose s; vaccines; therapeutic vaccines; vaccine preparations
Goods and Services
Medical research; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; preparation of cultures of microorganisms in the nature of bacterial and bacteriological preparations, all for medical and veterinary research purposes
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-07-17
Primary Code
005
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2019-07-17
Primary Code
042
First Use Anywhere Date
2017-07-11
First Use In Commerce Date
2017-07-11
Current Trademark Owners
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Heather E. Balmat
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2019-07-13NEW APPLICATION ENTERED IN TRAM
2019-07-17NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-07-18NOTICE OF DESIGN SEARCH CODE E-MAILED
2019-09-26ASSIGNED TO EXAMINER
2019-09-26NON-FINAL ACTION WRITTEN
2019-09-26NON-FINAL ACTION E-MAILED
2019-09-26NOTIFICATION OF NON-FINAL ACTION E-MAILED
2020-02-07TEAS RESPONSE TO OFFICE ACTION RECEIVED
2020-02-07CORRESPONDENCE RECEIVED IN LAW OFFICE
2020-02-08TEAS/EMAIL CORRESPONDENCE ENTERED
2020-02-28APPROVED FOR PUB - PRINCIPAL REGISTER
2020-03-18NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2020-04-07PUBLISHED FOR OPPOSITION
2020-04-07OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-06-02NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2020-10-06TEAS EXTENSION RECEIVED
2020-10-06EXTENSION 1 FILED
2020-10-06EXTENSION 1 GRANTED
2020-10-08NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-05-26TEAS EXTENSION RECEIVED
2021-05-26EXTENSION 2 FILED
2021-05-26EXTENSION 2 GRANTED
2021-05-28NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-11-09TEAS EXTENSION RECEIVED
2021-11-09EXTENSION 3 FILED
2021-11-09EXTENSION 3 GRANTED
2021-11-11NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED